|
業務類別
|
Biotechnology |
|
業務概覽
|
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) andother GCC-expressing cancers. |
| 公司地址
| 201 Haskins Way, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 695-0677 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.lyell.com |
| 員工數量
| 161 |
| Ms. Smital Shah, M.B.A. |
Chief Financial and Business Officer |
-- |
09/03/2026 |
| Dr. Lynn Seely,M.D. |
Director, President and Chief Executive Officer |
美元 690.17K |
09/03/2026 |
| Mr. Mark A. Meltz |
General Counsel and Corporate Secretary |
-- |
24/04/2026 |
| Ms. Veronica Sanchez Bulis |
Vice President, Corporate Controller and Principal Accounting Officer |
-- |
12/03/2026 |
| Dr. David R. Shook, M.D. |
Chief Medical Officer |
-- |
24/04/2026 |
| Mr. Stephen Hill |
Chief Operating Officer |
美元 529.47K |
24/04/2026 |
| Dr. Gary Lee, PhD |
Chief Scientific Officer |
美元 520.02K |
24/04/2026 |
|
|
| Ms. Catherine J. Friedman |
Lead Independent Director |
24/04/2026 |
| Dr. Otis W. Brawley,M.D. |
Independent Director |
24/04/2026 |
| Dr. Lynn Seely,M.D. |
Director, President and Chief Executive Officer |
09/03/2026 |
| Mr. William J. Rieflin |
Independent Director |
24/04/2026 |
| Mr. Mark L. Bachleda, M.B.A. |
Independent Director |
24/04/2026 |
| Dr. Richard D. Klausner, M.D. |
Chairman of the Board |
24/04/2026 |
| Dr. Elizabeth G. Nabel, M.D. |
Independent Director |
24/04/2026 |
| Dr. Sumant Ramachandra,M.D.,PhD |
Independent Director |
24/04/2026 |
|
|
|
|
